Mainstay Medical Interim Management Statement
Dublin, Ireland - 9 November 2015: Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, today issues this Interim Management Statement covering the period from 1 July 2015 to today's date.
More info on Mainstay Medical's website.
Next > Green Biologics starts construction in Little Falls, MN
Previous > Mainstay Medical Applies for CE Mark for ReActiv8®